Selectively expressed RNA molecules as a versatile tool for functionalized cell targeting.

Area of Science:

• Biotechnology
• Molecular Biology
• RNA Therapeutics

Background:

• Precise targeting of diseased cells is crucial for next-generation pharmaceuticals.
• Current methods often fail due to a lack of specific surface markers on target cells.

Purpose of the Study:

• To develop a novel RNA-based methodology for precise cell targeting and selective effector protein expression.
• To create a versatile platform technology for therapeutic and diagnostic applications.

Main Methods:

• Development of selectively expressed RNA molecules (seRNAs) by combining antisense technology, mRNA therapy, and functional RNA secondary structures.
• Designing seRNAs to remain inactive in non-target cells and activate via partial degradation in preselected cell types.
• Utilizing a modular system for adaptable cell specificity and functionalization.

Main Results:

• Demonstrated proof-of-concept for seRNAs as a highly selective cell-targeting platform.
• Successfully treated breast tumor cell clusters in mixed cell systems.
• Effectively reduced U87 glioblastoma cell clusters in the brains of male mice without observable side effects.

Conclusions:

• The developed seRNA technology enables precise cell targeting and selective therapeutic protein expression.
• This platform holds significant potential for diverse therapeutic applications, including cancer treatment.
• The modular design allows for easy adaptation to various cell types and medical needs.